Loading...

We've got a brand new version of Simply Wall St! Try it out

Helix BioMedix

OTCPK:HXBM
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HXBM
OTCPK
$8M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. The last earnings update was 2577 days ago. More info.


Add to Portfolio Compare Print
HXBM Share Price and Events
7 Day Returns
1.9%
OTCPK:HXBM
0.5%
US Biotechs
0.7%
US Market
1 Year Returns
-11%
OTCPK:HXBM
14.8%
US Biotechs
18.2%
US Market
HXBM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Helix BioMedix (HXBM) 1.9% 1.9% 1.9% -11% -11% 19.1%
US Biotechs 0.5% 8% 14.9% 14.8% 24% 3.8%
US Market 0.7% 1.5% 5% 18.2% 35.8% 52.7%
1 Year Return vs Industry and Market
  • HXBM underperformed the Biotechs industry which returned 14.8% over the past year.
  • HXBM underperformed the Market in United States of America which returned 18.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Helix BioMedix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Helix BioMedix is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Helix BioMedix has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Helix BioMedix. This is due to cash flow or dividend data being unavailable. The share price is $42.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Helix BioMedix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Helix BioMedix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:HXBM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2012-09-30) in USD Not available
OTCPK:HXBM Share Price ** OTCPK (2019-12-10) in USD $42
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 18.05x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.5x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Helix BioMedix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PE ratio to the industry average as no data exists.
  • Unable to calculate PE ratio for Helix BioMedix, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Helix BioMedix's expected growth come at a high price?
Raw Data
OTCPK:HXBM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 0x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 0.89x
United States of America Market PEG Ratio Median Figure of 2,046 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Helix BioMedix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Helix BioMedix's assets?
Raw Data
OTCPK:HXBM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2012-09-30) in USD Not available
OTCPK:HXBM Share Price * OTCPK (2019-12-10) in USD $42
United States of America Biotechs Industry PB Ratio Median Figure of 418 Publicly-Listed Biotechs Companies 3.08x
United States of America Market PB Ratio Median Figure of 5,089 Publicly-Listed Companies 1.78x

* Primary Listing of Helix BioMedix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to compare the PB ratio to the industry average as no data exists.

Next steps:

  1. Examine Helix BioMedix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Helix BioMedix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Helix BioMedix has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Helix BioMedix expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Helix BioMedix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Helix BioMedix expected to grow at an attractive rate?
  • Unable to compare Helix BioMedix's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Helix BioMedix's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Helix BioMedix's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:HXBM Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 21.5%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.2%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:HXBM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (7 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:HXBM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2012-09-30 2 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Helix BioMedix is high growth as no earnings estimate data is available.
  • Unable to determine if Helix BioMedix is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:HXBM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (7 years ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Helix BioMedix Company Filings, last reported 7 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HXBM Past Financials Data
Date (Data in USD Millions) EPS *
2012-09-30 -15.59

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Helix BioMedix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Helix BioMedix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Helix BioMedix's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Helix BioMedix's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Helix BioMedix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Helix BioMedix has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Helix BioMedix performed over the past 5 years?

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Helix BioMedix has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data. You can see them here.

Show me the analysis anyway

  • Helix BioMedix's last earnings update was 2577 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Helix BioMedix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Insufficient past earnings data to establish if Helix BioMedix's year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Helix BioMedix's 1-year growth to the 5-year average as past earnings data has not been reported.
  • Unable to compare Helix BioMedix's 1-year growth to the US Biotechs industry average as past earnings data has not been reported.
Earnings and Revenue History
Helix BioMedix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Helix BioMedix Company Filings, last reported 7 years ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:HXBM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2012-09-30 2.07 -2.58 3.37 0.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Unable to establish if Helix BioMedix has efficiently used shareholders’ funds last year as no Return on Equity data is available.
  • Unable to establish if Helix BioMedix has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as past financial data has not been reported.
  • Unable to establish if Helix BioMedix improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.

Next steps:

  1. Examine Helix BioMedix'sHelix BioMedix's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Helix BioMedix's filings and announcements here.
  3. Past financial records are usually unavailable for companies that have just been established or recently publicly listed, which makes them inherently riskier. Take a look at a list of well-established companies here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Past performance checks
We assess Helix BioMedix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Helix BioMedix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Helix BioMedix's financial health and their level of debt?

In this section we usually analyse Helix BioMedix's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Helix BioMedix has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information. You can see them here.

Show me the analysis anyway

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Helix BioMedix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unable to compare short term assets to short term liabilities as Helix BioMedix has not reported sufficient balance sheet data.
  • Unable to establish if Helix BioMedix's long term commitments exceed its cash and other short term assets as Helix BioMedix has not reported sufficient balance sheet data.
Balance sheet
This treemap shows a more detailed breakdown of Helix BioMedix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Unable to establish if Helix BioMedix has a high level of physical assets or inventory without balance sheet data.
  • Helix BioMedix has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Helix BioMedix Company Filings, last reported 7 years ago.

OTCPK:HXBM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2012-09-30 1.15 0.00 0.22
  • Helix BioMedix has no debt.
  • Helix BioMedix has not taken on any debt in the past 5 years.
  • Helix BioMedix has no debt, it does not need to be covered by operating cash flow.
  • Helix BioMedix has no debt, therefore coverage of interest payments is not a concern.

Next steps:

  1. Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  2. Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Helix BioMedix's financial data was last updated here.
  3. Companies with strong financial health are considered a less risky investment. Discover these stocks here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Financial health checks
We assess Helix BioMedix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Helix BioMedix has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Helix BioMedix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Helix BioMedix dividends.
If you bought $2,000 of Helix BioMedix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Helix BioMedix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Helix BioMedix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:HXBM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1960 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Helix BioMedix has not reported any payouts.
  • Unable to verify if Helix BioMedix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Helix BioMedix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Helix BioMedix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Helix BioMedix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Helix BioMedix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Helix BioMedix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Helix BioMedix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Robin Carmichael
COMPENSATION $304,350
AGE 62
TENURE AS CEO 2.4 years
CEO Bio

Ms. Robin L. Carmichael has been the Chief Executive Officer of Helix Biomedix Inc. since July 10, 2017 and its President since February 2015 and served as its Chief Operating Officer since January 12, 2011. Previously, Ms. Carmichael served as a Vice President of Marketing & Business Development at Helix Biomedix Inc. since October 31, 2007 and Vice President since January 12, 2011. She was responsible for the Helix Biomedix's marketing and business development functions, including product strategy, technology licensing, organizational management and strategic partnerships. She has over 20 years of sales and marketing experience in the healthcare industry, having held various sales management and marketing positions in the health and medical industries, including six years at Baxter Healthcare. Most recently, she served as Chief Operating Officer of DERMAdoctor, Inc., a prestige skin company, where she was responsible for its financial and business operations. She also expanded and implemented new business development and product plans with many leading retailers while strengthening the domestic and international distribution network. Prior to DERMAdoctor, she served as Vice President of Marketing of Photomedex Inc. She joined ProCyte Corp. in 1993 in the clinical research department and served as its Vice President of Marketing since 1998. From 1996 to 1997, she worked in ProCyte Corp.'s marketing department as a Product Manager and in 1997, was promoted to Director of Marketing. She held a number of medical regional and national sales positions prior to joining Procyte. She serves as a Director of Helix Biomedix Inc. She is a recognized speaker and author on numerous topics, including peptides and skin care products. Ms. Carmichael holds a Bachelor of Science in Nursing from Seattle University and attended the UCLA Anderson Graduate School of Executive Management.

CEO Compensation
  • Insufficient data for Robin to compare compensation growth.
  • Insufficient data for Robin to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team

R. Beatty

TITLE
Executive Chairman & Chief Investor Officer
COMPENSATION
$414K
AGE
69

Robin Carmichael

TITLE
President
COMPENSATION
$304K
AGE
62
TENURE
2.4 yrs

Kelly Forsythe

TITLE
Associate Director of Marketing
Board of Directors Tenure

Average tenure and age of the Helix BioMedix board of directors in years:

9.8
Average Tenure
68
Average Age
  • The tenure for the Helix BioMedix board of directors is about average.
Board of Directors

R. Beatty

TITLE
Executive Chairman & Chief Investor Officer
COMPENSATION
$414K
AGE
69
TENURE
4.8 yrs

Robin Carmichael

TITLE
President
COMPENSATION
$304K
AGE
62

Richard Cohen

TITLE
Director
COMPENSATION
$24K
AGE
68
TENURE
14 yrs

Jack Clifford

TITLE
Director
COMPENSATION
$22K
AGE
76
TENURE
12.3 yrs

Zoe Draelos

TITLE
Member of Scientific Advisory Board

Lawrence Jones

TITLE
Director
COMPENSATION
$21K
AGE
68
TENURE
9.8 yrs

Will Goolsbee

TITLE
Director
AGE
65
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Helix BioMedix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Helix BioMedix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.

Details
Name: Helix BioMedix, Inc.
HXBM
Exchange: OTCPK
Founded: 1988
$8,461,285
205,371
Website: http://www.helixbiomedix.com
Address: Helix BioMedix, Inc.
22121-17th Avenue SE,
Suite 112,
Bothell,
Washington, 98021,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK HXBM Common Stock Pink Sheets LLC US USD 26. Jul 1995
Number of employees
Current staff
Staff numbers
0
Helix BioMedix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/12/10 23:38
End of day share price update: 2019/12/10 00:00
Last earnings filing: 2012/11/19
Last earnings reported: 2012/09/30
Last annual earnings reported: 2011/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.